ArticleBrain, behavior, & immunity - health2026
Mania and psychosis following chimeric antigen receptor T-cell therapy: A report of two cases and mechanistic discussion.
Article in Brain, behavior, & immunity - health, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
CD20. CD19-targeted chimeric antigen receptor modified T-cell immunotherapy (CAR T-cell therapy) is an experimental CAR with increasing use for the treatment of lymphoid malignancies. Although acute neuropsychiatric toxicities are well described following CAR T-cell therapies, late-onset persistent neuropsychiatric symptoms, including mania and psychosis, are poorly characterized, and their underlying mechanisms are unknown. Here, we present two cases of new-onset mania and psychosis in the months following dual targeted CD20. CD19 CAR T-cell therapy, contributing significantly to the literature wherein no cases of such have been reported. We discuss the published literature on chronic neuropsychiatric symptoms following CAR T-cell therapy as well as potential neurobiological mechanisms for these effects. Finally, we discuss therapeutic considerations including the potential role of second-generation antipsychotics, such as olanzapine, which may be effective in the treatment of late-onset and persistent neuropsychiatric symptoms, including psychosis, following CAR-T cell treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.